The Food and Drug Administration (FDA) has approved EluRyng (etonogestrel/ethinyl estradiol vaginal ring; Amneal), the first generic version of NuvaRing (Merck), for use by females of reproductive age to prevent pregnancy.
The vaginal ring releases on average 0.12 mg/d of etonogestrel, a progestin, and 0.015 mg/d of ethinyl estradiol, an estrogen. One ring is inserted in the vagina and must remain in place continuously for 3 weeks. It is removed for a 1-week break, during which a withdrawal bleed usually occurs. A new ring is inserted 1 week after the last ring was removed.
Each EluRyng is individually packaged in its own pouch; each carton contains 3 pouches. In a press release, Amneal stated that the launch of EluRyng will begin on December 12, 2019.
For more information visit amneal.com.
This article originally appeared on MPR